Neuropeptide control of ocular growth

Details Neuropeptide control of ocular growth Neuropeptide control of ocular growth

1990-02-22

1991-10-08

Page, Thurman K.

Drug, bio-affecting and body treating compositions

Preparations characterized by special physical form

Implant or insert

424422, 424423, 424428, 514 12, 514 21, 514912, 514929, 530324, 530843, 530844, A61F 200, A61K 3700, A61K 3702

Patent

active

050553020

ABSTRACT:
A method and composition for inhibition of abnormal postnatal ocular growth are disclosed. The composition comprises vasoactive intestinal peptide (VIP), PHI or a analogue of these peptides. The method for inhibition of abnormal postnatal ocular growth comprises administering to the eye of an animal effective amount of VIP, PHI or analogue of these peptides.

REFERENCES:
patent: 3862927 (1975-01-01), Said et al.
patent: 4745100 (1988-05-01), Gilbard et al.
Increase in Retinal VIP After Eyelid Fusion in Primates, Stone et al., PNAS, , 257, 1988.
Different Effects of Substance P and VIP on the Motor Function of Bovine Intraocular Muscles, Suzuki et al., Invest. Ophthalmol. Vis. Sci., 24, 1566, 1983.

Affiliated with

Also associated with

Rating

Neuropeptide control of ocular growth does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Neuropeptide control of ocular growth, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Neuropeptide control of ocular growth will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-256053